

# WEEKLY REPORT

07/06/2024



## **CONITEC RECOMMENDS PARTIAL INCLUSION OF TREATMENTS FOR PROSTATE CANCER**

At a meeting of the Medicines Committee of the National Commission for the Incorporation of Technologies into the Unified Health System (Conitec) held this Wednesday (03), contributions received in public consultations on medicines for the treatment of prostate cancer were analyzed. The incorporation of abiraterone was recommended for the treatment of castration-sensitive and metastatic prostate cancer and individuals with non-metastatic and metastatic castration-resistant prostate cancer (CRPC) in treatment-naïve patients and metastatic in patients with prior chemotherapy use. However, the use of enzalutamide, darolutamide and apalutamide were recommended not to be incorporated. [Read more.](#)

## **BILL THAT ENCOURAGES COMPANIES TO HIRE MEN WITH PROSTATE CANCER IS APPROVED**

The Labor Committee of the House of Representatives approved Bill 687/2024, by Congresswoman Silvia Waiãpi (PL-AP), which creates the Blue Company program and the Blue Seal, with incentives for companies that hire men diagnosed or undergoing treatment for prostate cancer. The text establishes differentiated working conditions without reduced pay for men in these situations, such as: remote work; reduced working hours; flexible schedules; psychological and social support; It is guarantee of job stability. Companies that participate in the program will receive the Blue Seal and will be entitled to the following benefits: public recognition (the seal may be used in advertising materials); access to training and guidance courses for hiring and reintegrating men with prostate cancer into the job market; It is The Blue Seal may be used as a tiebreaker in bids with direct and indirect public administration. Certification may be revoked in case of non-compliance with labor legislation. [Read more.](#)

## **SENATOR SAYS VETO CAN BE OVERTURNED TO RESUME LIMIT TO POST-TRIAL ACCESS**

The presidential veto of the Bill that regulates clinical research with human beings (PL 6.007/2023), specifically the section that provides for a period of five years for the supply of medicines to research participants, making the obligation of the companies responsible for the studies continues to be for life, it has a great chance of being overturned by the National Congress. This is the assessment of senator Dr. Hiran Gonçalves (PP-RR). "We cannot say whether this happens before or after the upcoming elections, but the possibility that this veto will be reversed is very high," said the parliamentarian last Tuesday night (2). [Read more.](#)

## **NEW VERSION OF BILL ABOUT TAX REFORM REDUCES REVIEW PERIOD FOR DRUGS WITH TAX BENEFITS**

The House of Representative's working group on tax reform regulation reduced the review period for lists of reference medicines, accessibility devices for people with disabilities and exempt medical devices from 1 year to 120 days. Furthermore, the opinion gives approval for the Public Authorities to exempt medicines and medical devices in cases of public health emergencies. The tax reduction will be valid for the duration of the health calamity. The Working Group rejected any changes to the lists of medicines with favorable taxation. There are three lists: one with a zero IBS/CBS rate, for cancer medicines; one with a 60% reduction in the IBS/CBS rate, for a list of medications; and another with a full aliquot, which contains dipyrrone, paracetamol, and other anti-inflammatories. [Read more.](#)

## **MINISTER OF HEALTH RULES OUT REVIEW OF CORRECTION OF MINIMUM INVESTMENT FLOORS IN HEALTH AND EDUCATION**

The Minister of Management and Innovation in Public Services, Esther Dweck, ruled out reviewing how to correct the minimum investment floors in health and education, currently linked to the growth in revenue. She also said that the government is not discussing the decoupling of social security and assistance benefits from the policy of increasing the minimum wage. The minister's statements were made in an interview with CNN Brasil, broadcast this Saturday, and reinforce statements that have been made by President Luiz Inácio Lula da Silva, despite studies being conducted by the technical areas of the Ministries of Finance and Planning and Budget. [Read more.](#)

## **MINISTRY OF HEALTH WANTS TO CENTRALIZE THE PURCHASE OF CANCER DRUGS**

The Ministry of Health wants to expand the centralized purchase of drugs for cancer treatment. In an interview with Jota, the Secretary of Specialized Care, Adriano Massuda, stated that the measure is inspired by the strategy adopted in the HIV-Aids Program, which invested in the purchasing power of the State, associated with policies for productive development to guarantee treatments for patients. Just as occurred in the HIV-Aids program, the idea is to expand the use of protocols and technical guidelines, in order to guarantee treatment for patients across the country. [Read more.](#)

## **CEARÁ LEGISLATIVE ASSEMBLY WILL ANALYZE BILL THAT AIMS TO ESTABLISH FABRY DISEASE AWARENESS DAY**

Representative Marta Goncalves (PL-CE) presented, in the Legislative Assembly of Ceará, Bill 503/2024, proposing the establishment of the State Fabry Disease Awareness Day. The text suggests that on disease awareness day, public actions should be carried out in partnership with medical entities, universities, associations and civil society, in the form of events, information lectures and training on the signs and symptoms of Fabry disease, so to expand knowledge and anticipate its diagnosis, as well as in the form of debates about the impacts generated on the lives of patients and families, in order to give visibility to the disease in society. [Read more.](#)

## **GENERIC DRUGS HAVE A DIFFERENCE OF UP TO 686% IN SÃO PAULO, ACCORDING TO PROCON**

A survey carried out by Procon -SP in physical stores and pharmacy websites in São Paulo showed that medicines sold in the State have price differences of up to 686%, in the case of generics, and up to 124% between reference medicines. The biggest discrepancy was found in Presidente Prudente, in the interior of São Paulo, where the price of the generic drug nimesulide 100 mg, with 12 tablets, varied from R\$2.99 to R\$23.49. [Read more.](#)

### **MORE HIGHLIGHTS**

[Anvisa informs about changes in administrative treatments for imports](#)

[Anvisa publishes a platform for patients to compare which similar drug can be used instead of branded medicine](#)

[Congresswoman withdraws bill aiming to halt the effects of not incorporating medication for neuromyelitis optica](#)

[Congressman presents opinion for the rejection of bills about suspension of the adjustment of the price of drugs](#)

[Brazil should participate in trials of the new Alzheimer's vaccine in 2026](#)

**BRAZIL NEWS**

[Haddad affirms Lula's commitment to fiscal responsibility](#)

[Lula wants to include meat in tax-exempt basic food basket](#)

[Group of highly indebted people grows to highest level since October](#)

[Brazil's industrial output falls less than expected in May](#)

[Brazil's Bolsonaro hopes for Trump return at right-wing rally](#)

[Argentina's Milei doubles down on Lula criticism as war of words heats](#)

[Argentina's Milei to speak at right-wing rally in Brazil](#)

[Brazil says G20 sherpas to avoid thorny issues at prep meetings](#)

[Brazilian industry reps to travel with Lula to Bolivia in bid to obtain cheaper gas](#)

[Brazil authority suspends Meta's AI privacy policy, seeks adjustment](#)

[Brazil sues Syngenta for alleged environmental damage](#)

[Brazil court orders environmental workers to resume licensing, fire prevention despite strike](#)



---

Relações Governamentais